How PTSD Develops and Persists After Traumatic Events

When Survival Responses Become Trapped in Time

Approximately 70% of adults worldwide experience at least one traumatic event in their lifetime. Of those, roughly 20% develop post-traumatic stress disorder (PTSD), according to research published in the Journal of Traumatic Stress. In the United States, the National Center for PTSD estimates a lifetime prevalence of 6.8%, with considerably higher rates in specific populations: 30% among Vietnam veterans, 20–30% among survivors of sexual assault, and 45–50% among survivors of rape, the highest rates associated with any trauma type. PTSD is not a sign of weakness — it represents a specific dysregulation of normal fear-learning mechanisms, and understanding its neurobiology has transformed treatment approaches dramatically since the 1990s.

DSM-5 Diagnostic Criteria

The DSM-5 (2013) reorganized PTSD into four symptom clusters, requiring exposure to actual or threatened death, serious injury, or sexual violence (directly, witnessed, or through indirect trauma exposure):

Symptoms must last more than one month and cause significant functional impairment. A dissociative subtype (featuring depersonalization and derealization) is recognized for approximately 14% of PTSD patients and shows different neurobiological profiles.

Fear Memory and Extinction Failure

Under normal circumstances, the brain learns to fear threats through classical conditioning: a dangerous stimulus (the unconditioned stimulus) becomes paired with a conditioned stimulus (the context or cue present during the threat), producing a conditioned fear response. After the danger passes, repeated safe exposure to the conditioned stimulus without the threat leads to fear extinction — the amygdala-dependent suppression of fear responses through new inhibitory learning, primarily mediated by the infralimbic prefrontal cortex.

In PTSD, this extinction process fails. The amygdala encodes the traumatic event with extraordinary persistence — enhanced by the massive norepinephrine release during the trauma, which strengthens memory consolidation. The ventromedial prefrontal cortex (vmPFC), which normally inhibits amygdala activity during safety signaling, shows reduced activity and reduced gray matter volume in PTSD. The hippocampus — required for contextual discrimination — is also reduced in volume, impairing the ability to recognize that a remembered trauma belongs to the past and not the present.

The Neurobiology of PTSD

• HPA axis dysregulation: paradoxically, PTSD patients often show low cortisol levels (hypocortisolism) despite elevated sympathetic tone — possibly due to enhanced negative feedback sensitivity; this contrasts with depression, which shows hypercortisolism
• Norepinephrine hyperactivity: the locus coeruleus fires excessively; elevated norepinephrine contributes to hyperarousal, exaggerated startle, and sleep disturbance; prazosin (alpha-1 adrenergic antagonist) reduces PTSD nightmares by blocking NE effects in prefrontal cortex
• Glucocorticoid receptor supersensitivity: enhanced HPA feedback causes cortisol to suppress its own release too aggressively, resulting in chronically low baseline cortisol while reactivity is heightened
• Fear generalization: reduced hippocampal volume impairs contextual learning, causing fear responses to generalize to safe situations that share superficial features with the trauma context

Risk and Protective Factors

Not everyone exposed to trauma develops PTSD. Risk stratification involves both pre-trauma and peri-trauma factors:

• Risk factors: prior trauma history, prior psychiatric disorder, female sex (women develop PTSD at twice the rate of men after equivalent trauma), interpersonal violence (vs. natural disaster), low social support, peritraumatic dissociation, acute stress disorder in the immediate aftermath
• Protective factors: strong social support networks, higher pre-trauma cognitive reserve, meaning-making ability, post-trauma social reconnection, early access to evidence-based care
• Genetic factors: variants in the FKBP5 gene (a regulator of glucocorticoid receptor sensitivity), the serotonin transporter promoter (5-HTTLPR), and BDNF genes interact with trauma exposure to influence PTSD risk

Evidence-Based Treatments

Trauma-focused psychotherapies are substantially more effective than medication alone for PTSD, producing remission rather than mere symptom suppression in most responders. Early intervention — within weeks of trauma exposure — with cognitive restructuring and supported gradual exposure may prevent chronification.

This article is for informational purposes only. Consult a qualified healthcare professional for medical advice.